Just one cautionary note. The 9.5% annual event rate for ACS patients with diabetes that is quoted in the figure on slide 13 "Patient Enrichment Strategy" is not calculated from BETonMACE data. This number is from: "Sources: Calculated from CDC Heat Disease Facts; Holden, SE. et al. 2015; White, WB. et al. 2013; Kim, H. et al. 2015; Cardarelli, F. et al. 2008; Okada, T. et al. 2008." All we have been told is that the average approximate events per 100 patient years in the blinded BETonMACE trial (includes all patients regardless of treatment) is 8 per 100 patient years. We have no idea what the annual event rate (aka events per 100 patient years) will be in the control group in BETonMACE. 

BearDownAZ